By Saadia Aslam An FDA review of study findings showed a potential increased risk of cardiac arrhythmias in patients with pre-existing cardiac disease who are…
View More Lamotrigine may be associated with increased risk of cardiac arrhythmias, FDA warns(Taken from Expert Analysis- ACC) This secondary analysis from the EMPEROR-Reduced trial shows that use of empagliflozin reduces the risk of CV death or HF…
View More Beyond Diabetes: The Impact of Empagliflozin in Heart Failure with Reduced Ejection Fraction
By Saadia Aslam Despite an upsurge in the incidence of atherosclerotic cardiovascular diseases (ASCVD) among young adults, the attributable risk of recreational substance use among…
View More Recreational substances associated with a higher likelihood of premature atherosclerotic cardiovascular disease
By Ahmed El-Medany In contrast to their prevalence in the overall disease population, Black individuals were considerably underrepresented in trials that affirmed the United States’…
View More Underrepresentation of black participants in key Cardiology trials
By Ahmed El-Medany In a large retrospective study by Venetsanos et al, researchers analysed 37,990 patients from the SWEDEHEART registry with myocardial infarction (MI) who…
View More Prasugrel and ticagrelor associated with similar efficacy and safety following myocardial infarction
Emer Joyce speaks about the impact COVID-19 has had on the clinical landscape of acute cardiac, intensive care and cardiomyopathy/heart failure services including the wide spectrum…
View More COVID‐19, myocarditis, and the other side of the bed
Announcement on the staging of the 2021 edition of the BCS Annual Conference
View More BCS Announcement On The Annual Conference 2021